Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoRPHCF 92 EV-to-EBIT is 10.19 as of Jul. 23, 2026, which is 34% below its 10-year median of 15.53. GuruFocus rates RPHCF with a GF Score™ of 92/100 and a GF Value™ of $21.04. The stock has 2 warning signs investors should review. Among 1,559 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks better than 55.16% on this metric.
Rohto Pharmaceutical Co (OTCPK:RPHCF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Rohto Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was $3,383 Mil.
Rohto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $318 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co EV-to-EBIT Related Terms
Rohto Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's EV-to-EBIT falls into.
Rohto Pharmaceutical Co's current Enterprise Value is $3,246 Mil.
Rohto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $318 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co (RPHCF) has a EV-to-EBIT of 10.19 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rohto Pharmaceutical Co and its competitors. This is 34% below median its historical median of 15.53. Over the past decade, Rohto Pharmaceutical Co's EV-to-EBIT has ranged from 9.96 to 24.12. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #699 out of 1559 companies in the Consumer Packaged Goods industry, placing it in the top 44.8%.
Is Rohto Pharmaceutical Co's EV-to-EBIT too high?
Rohto Pharmaceutical Co's current EV-to-EBIT of 10.19 is 34% below median its 10-year median of 15.53. Over the past 10 years, this metric has ranged from a low of 9.96 to a high of 24.12. The Consumer Packaged Goods industry median EV-to-EBIT is 12.11. Rohto Pharmaceutical Co's value of 10.19 is 15.9% below this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #699 out of 1559 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's EV-to-EBIT compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #699 out of 1559 companies for EV-to-EBIT. This puts Rohto Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBIT is 12.11. Rohto Pharmaceutical Co's value of 10.19 is 15.9% below this benchmark. Historically, Rohto Pharmaceutical Co's own EV-to-EBIT has ranged from 9.96 to 24.12 over the past decade. While the company's 10-year median is 15.53 vs. the industry median of 12.11, Rohto Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.11, based on 1,559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current EV-to-EBIT of 10.19 is 15.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current EV-to-EBIT is 10.19, which is 34% below median its own 10-year median of 15.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current EV-to-EBIT of 10.19. The stock's GF Value™ is $21.04, compared to a current price of $15.00 — trading 28.7% below its estimated fair value. The current EV-to-EBIT is 10.19, which is 34% below median its 10-year median of 15.53 and 15.9% below the Consumer Packaged Goods industry median of 12.11. Rohto Pharmaceutical Co's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current EV-to-EBIT is 10.19 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of $15.00 is trading 28.7% below its estimated GF Value™ of $21.04.
Key valuation signals for RPHCF:
EV-to-EBIT: 10.19 (34% below median its 10-year median of 15.53)
GF Value™: $21.04 vs. price of $15.00 (28.7% below fair value)
Industry Position: 15.9% below the Consumer Packaged Goods median (#699 of 1559)
No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
92GF Score
Get the complete analysis for RPHCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPHCF has been successfully added to your 
